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BACKGROUND Gender-based data on chest pain after PCI with newer
generation DES are scarce. The aim of this study is to assess gender
differences in chest pain following percutaneous coronary interven-
tion (PCI) with newer generation drug-eluting stents (DES).
METHODS We performed a patient-level pooled analysis of the
TWENTE and DUTCH PEERS randomized trials that enrolled a broad
patient population, treated with newer generation permanent poly-
mer-coated DES. The primary clinical endpoint is target vessel failure
(TVF), a composite of cardiac death, target vessel-related myocardial
infarction (MI), or target vessel revascularization. At 1 and 2-years,
clinical follow-up was available in 99.9% and patient-reported chest
pain data in 94.1% and 93.6%.
RESULTS Among all 3,202 patients, the 871 (27.2%) women were
older (67.510.2 years vs. 62.810.6 years, p<0.001) and had more
cardiovascular risk factors than men, such as diabetes (24.2% vs.
17.8%, p<0.001), hypertension (63.6% vs. 51.6%, p<0.001), and a
positive family history for coronary disease (54.5% vs. 50.1%,
p¼0.03). At 1 and 2-year follow-up, women had more clinically
relevant chest pain than men (16.3% vs. 10.5%, p<0.001, and 17.2%
vs. 11.1%, p<0.001, respectively). Multivariate analysis demonstrated
that female gender independently predicted clinically relevant chest
pain at 1 and 2-year follow-up (adjusted OR:1.7, 95%-CI:1.4–2.2,
p<0.001; adjusted OR:1.6, 95%-CI:1.3–2.1, p<0.001, respectively).
Nevertheless, the 2-year rates of TVF (9.4% vs. 9.5%, p¼0.93) were
almost identical for both genders.
CONCLUSIONS While after PCI with newer generation DES the inci-
dence of adverse cardiovascular events was low and similar for both
genders, women showed a signiﬁcantly higher prevalence of clinically
relevant chest pain that appears to be largely related to mechanisms
other than epicardial coronary obstruction.
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BACKGROUND The ALPHA coronary stent delivery system includes a
cobalt-chromium, ﬂexible, thin-strut platform, a bio-stable and
biocompatible ﬂuoro-polymer based drug carrier, sirolimus and a
hydrophilic, rapid-exchange delivery catheter. It is designed to create
a competitive alternative to other drug-eluting coronary stents sys-
tems. Herein, we report the initial 2-year outcomes of 781 patients
(pts) treated with the ALPHA stent.
METHODS Consenting pts. were treated with one or more ALPHA
stents and followed by trained research coordinators. Angiographic
and follow-up angiography was evaluated by a central angiographic
core laboratory.
RESULTS Pts. averaged 58 years of age and 66% were male. Hyper-
tension was present in 57%. Most pts. presented with unstable angina
(78%). Sites of stent implantation included the LAD (55%), LCX (20%)
and RCA (25%). Based on angiographic core lab measurements,
average lesion length was 21 mm and average reference diameter was
2.8mm. Most pts. (69%) had a single lesion treated and 1.6 stents were
deployed per pt. Transradial access was used in 83%. Two-year
follow-up was available in 768 (98%) pts. The incidence of all-cause
death was 0.9% with cardiac death being 0.4%. The rate of target
lesion revascularization was 0.7%. Myocardial infarction was
observed in 1.3%. Importantly total MACE was 2.2% and no pt.experienced thrombosis of the Alpha stent. Angiographic follow-up
was completed in 87% of 205 pts. Lesion length and reference diam-
eter were 21þ13 mm and 2.8þ0.7mm respectively. In-stent late loss
was 0.07 mm and in-segment late loss was 0.04: mm. Binary reste-
nosis rate was 1.0%.
CONCLUSIONS The ALPHA stent was designed on the basis of the
most contemporary knowledge of stent technology. This observa-
tional study demonstrates the ALPHA stent can achieve high rates of
sustained patency with low rates of stent-related adverse events.
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BACKGROUND Stent thrombosis (ST) is an undesirable consequence
of intracoronary stents, commonly presenting as myocardial infarc-
tion and at times death. Efforts to reduce the occurrence of ST have
included the use of biodegradable polymers. Whether this modiﬁca-
tion of stent design reduces ST is unclear
METHODS The ALPHA coronary stent includes a ﬂexible, cobalt-
chromium platform, a bio-stable and bio-compatible ﬂuoro-polymer
based drug carrier and sirolimus. We conducted a randomized, sin-
gle blinded trial to compare the angiographic (9-months) and clinical
(12-months) outcomes of ALPHA (n¼205) to EXCEL (n¼202), also a
sirolimus eluting stent but with a bio-degradable polymer.
RESULTS There were no signiﬁcant (p>0.05) differences in baseline
clinical or angiographic features, number of stents deployed or
initial success rates. At 9-months, angiographic late loss (angio-
graphic core laboratory, LL) was 0.07 mm and 0.10 mm (P¼NS) in
ALPHA and EXCEL stents respectively. Maximal LL across stent
segments was lower in ALPHA compared to EXCEL patients
(0.20mm vs. 0.25mm, p¼0.02). At 12-months, clinical events were
low in both stent groups (table). No patient receiving the ALPHA
stent experienced ST while ST was observed in 0.5% of those treated
with EXCEL.
CONCLUSIONS Excellent angiographic and clinical results, including
avoiding stent thrombosis, may be obtained with the ALPHA sirolimus
eluting stent and a stable polymer.Event at 12-months ALPHA EXCEL P valueAll Cause Death 0.5% 1.0% 0.22Myocardial Infarction 1.0% 1.5% 0.69Any TLR 1.5% 3.0% 0.09ARC Thrombosis 0% 0.5% 0.50CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Sirolimus, Stent development, Stent thrombosis, late
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BACKGROUND Fast releasing, rapamycin eluting stents although
safe, showed inferior results with regard to inhibition of restenosis.
Therefore, we report vascular effects of the novel, biodegradable
polymer stent matrix with elevated sirolimus dose and fast release
kinetics (ed-frSES, Alex, Balton) in the porcine coronary in stent
restenosis model.
METHODS A total of 19 stents were implanted with 120% overstretch
in coronary arteries of 7 domestic pigs: 7 ed-frSES with 1.3 mg/mm2 of
